TY - JOUR
T1 - Metabolic modulation
T2 - A new therapeutic target in treatment of heart failure
AU - Palaniswamy, Chandrasekar
AU - Mellana, William Michael
AU - Selvaraj, Dhana R.
AU - Mohan, Diwakar
PY - 2011/11
Y1 - 2011/11
N2 - Treatment of heart failure involves management of risk factors and control of symptoms. Traditional management of heart failure involves the use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, diuretics, aldosterone antagonists, and digitalis. Metabolic modulators are a newer class of drugs that benefit these patients by modulating cardiac metabolism without altering hemodynamics. They have the potential to relieve symptoms in patients with refractory heart failure who are already on optimal medical therapy. These drugs increase glucose metabolism at the expense of free fatty acid metabolism, thereby enhancing efficient use of oxygen. This review discusses the role of 4 metabolic modulators drugs that could potentially be used for heart failure therapy: trimetazidine, ranolazine, perhexiline, and etomoxir.
AB - Treatment of heart failure involves management of risk factors and control of symptoms. Traditional management of heart failure involves the use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, diuretics, aldosterone antagonists, and digitalis. Metabolic modulators are a newer class of drugs that benefit these patients by modulating cardiac metabolism without altering hemodynamics. They have the potential to relieve symptoms in patients with refractory heart failure who are already on optimal medical therapy. These drugs increase glucose metabolism at the expense of free fatty acid metabolism, thereby enhancing efficient use of oxygen. This review discusses the role of 4 metabolic modulators drugs that could potentially be used for heart failure therapy: trimetazidine, ranolazine, perhexiline, and etomoxir.
KW - etomoxir
KW - metabolic modulators
KW - perhexiline
KW - ranolazine
KW - trimetazidine
UR - http://www.scopus.com/inward/record.url?scp=81755184785&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81755184785&partnerID=8YFLogxK
U2 - 10.1097/MJT.0b013e3181d70453
DO - 10.1097/MJT.0b013e3181d70453
M3 - Article
C2 - 20393344
AN - SCOPUS:81755184785
SN - 1075-2765
VL - 18
SP - e197-e201
JO - American Journal of Therapeutics
JF - American Journal of Therapeutics
IS - 6
ER -